Vasodilator therapy with hydralazine induces angiotensin AT 2 receptor-mediated cardiomyocyte growth in mice lacking guanylyl cyclase-A

British Journal of Pharmacology

Volumn 159, Issue 5, 2010, Pages 1133-1142

  Li, Y ^a   Saito, Y ^b   Kuwahara, K ^a   Rong, X ^a   Kishimoto, I ^c   Harada, M ^a   Horiuchi, M ^d   Murray, M ^e   Nakao, K ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NARA MEDICAL UNIVERSITY   (Japan)

^c NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^d EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Angiotensin; Heart; Hypertrophy; Natriuretic peptide; Receptor; Vasodilator, hydralazine

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; COLLAGEN TYPE 1; DRINKING WATER; GUANYLATE CYCLASE; HYDRALAZINE; MESSENGER RNA; NATRIURETIC FACTOR; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG MECHANISM; GENE EXPRESSION; GENOTYPE; HEART DEVELOPMENT; HEART FAILURE; HEART LEFT VENTRICLE; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART VENTRICLE; HEART VENTRICLE HYPERTROPHY; HYPOTENSION; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WILD TYPE;

ANIMALS; BLOOD PRESSURE; CARDIOMEGALY; FIBROSIS; GENE EXPRESSION; HYDRALAZINE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCYTES, CARDIAC; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, ATRIAL NATRIURETIC FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VASODILATOR AGENTS;

EID: 77949372169     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00619.x     Document Type: Article

References (45)

1. Bauer JA, Fung HL (1991). Concurrent hydralazine administration prevents nitroglycerin-induced hemodynamic tolerance in experimental heart failure. Circulation 84: 35-39.
2. Bhatnagar RS, Rapaka SSR, Liu TZ, Wolfe SM (1972). Hydralazine-induced disturbances in collagen biosynthesis. Biochim Biophys Acta 271: 125-132.
3. D'Amore A, Black MJ, Thomas WG (2005). The angiotensin II type 2 receptor causes constitutive growth of cardiomyocytes and does not antagonize angiotensin II type 1 receptor-mediated hypertrophy. Hypertension 46: 1347-1354.
4. Fenje P, Leenen FH (1985). Effects of minoxidil on blood pressure and cardiac hypertrophy in two-kidney, one-clip hypertensive rats. Can J Physiol Pharmacol 63: 161-164.
5. Gerber JG, Nies AS (1990). Ahtihypertensive agents and the drug therapy of hypertension. In: Gilman AG, Rall TW, Nies AS, Taylor P (eds). The Pharmacological Basis of Therapeutics. Pergamon Press: New York, pp. 784-813.
6. Gogia H, Mehra A, Parikh S, Raman M, Ajit-Uppal J, Johnson JV et al. (1995). Prevention of tolerance to hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure. J Am Coll Cardiol 26: 1575-1580.
7. Heart Failure Society of America (2006). Executive summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail 12: 10-38.
8. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG et al. (2005). American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. Circulation 112: e154-e235.
9. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG et al. (2009a). 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119: e391-e479.
10. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG et al. (2009b). 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 53: e1-e90.
11. Hunyady L, Turu G (2004). The role of the AT1 angiotensin receptor in cardiac hypertrophy: angiotensin II receptor or stretch sensor? Trends Endocrinol Metab 15: 405-408.
12. Ichihara S, Senbonmatsu T, Price E Jr, Ichiki T, Gaffney FA, Inagami T (2001). Angiotensin type 2 receptor is essential for ventricular hypertrophy and cardiac fibrosis in chronic angiotensin II-induced hypertension. Circulation 104: 346-351.
13. Kleaveland JP, Reichek N, McCarthy DM, Chandler T, Priest C, Muhammed A et al. (1986). Effects of six-month afterload reduction therapy with hydralazine in chronic aortic regurgitation. Am J Cardiol 57: 1109-1116.
14. Knowles HJ, Tian YM, Mole DR, Harris AL (2004). Novel mechanism of action for hydralazine: induction of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by inhibition of prolyl hydroxylases. Circ Res 95: 162-169.
15. Leenen FH, Prowse S (1987). Time-course of changes in cardiac hypertrophy and pressor mechanisms in two-kidney, one-clip hypertensive rats during treatment with minoxidil, enalapril or after uninephrectomy. J Hypertens 5: 73-83.
16. Leenen FH, Smith DL, Farkas RM, Reeves RA, Marquez-Julio A (1987). Vasodilators and regression of left ventricular hypertrophy. Hydralazine versus prazosin in hypertensive humans. Am J Med 82: 969-978.
17. Li Y, Kishimoto I, Saito Y, Harada M, Kuwahara K, Izumi T et al. (2002). Guanylyl cyclase A inhibits angiotensin II type 1a receptor-mediated cardiac remodeling, an endogenous protective mechanism in the heart. Circulation 106: 1722-1728.
18. Li Y, Kishimoto I, Saito Y, Harada M, Kuwahara K, Izumi T et al. (2004). Androgen contributes to gender-related cardiac hypertrophy and fibrosis in mice lacking the gene encoding guanylyl cyclase-A. Endocrinology 145: 951-958.
19. Li Y, Saito Y, Kuwahara K, Rong X, Kishimoto I, HaradaMet al. (2009). Guanylyl cyclase-A inhibits angiotensin II type 2 receptor-mediated pro-hypertrophic signaling in the heart. Endocrinology 150: 3759-3765.
20. Lopez JJ, Lorell BH, Ingefinger JR, Weinberg EO, Schunkert H, Diamant D et al. (1994). Distribution and function of cardiac angiotensin AT1- and AT2-receptor subtypes in hypertrophied rat hearts. AM J Physiol 267: H844-H852.
21. Lopez MJ, Wong SKF, Kishimoto I, Dubois S, Mach V, Friesen J et al. (1995). Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide. Nature 378: 65-68.
22. Mifune M, Sasamura H, Shimizu-Hirota R, Miyazaki H, Saruta T (2000). Angiotensin II type 2 receptors stimulate collagen synthesis in cultured vascular smooth muscle cells. Hypertension 36: 845-850.
23. Mukherjee D, Sen S (1993). Alteration of collagen phenotypes in hypertensive hypertrophy: role of blood pressure. J Mol Cell Cardiol 25: 185-196.
24. Murad S, Tajima S, Pinnell SR (1985). A paradoxical effect of hydralazine on prolyl and lysyl hydroxylase activities in cultured human skin fibroblasts. Arch Biochem Biophys 241: 356-363.
25. Nakanishi M, Saito Y, Kishimoto I, Harada M, Kuwahara K, Takahashi N et al. (2005). Role of natriuretic peptide receptor GC-A in myocardial infarction evaluated using genetically engineered mice. Hypertension 46: 441-447.
26. Nakayama T, Soma M, Takahashi Y, Rehemudula D, Kanmatsuse K, Furuya K (2000). Functional deletion mutation of the 5′-flanking region of type A human natriuretic peptide receptor gene and its association with essential hypertension and left ventricular hypertrophy in the Japanese. Circ Res 86: 841-845.
27. Norton GR, Tsotetsi J, Trifunovic B, Hartford C, Candy GP, Woodiwiss AJ (1997). Myocardial stiffness is attributed to alterations in crosslinked rather than total collagen or phenotypes in spontaneously hypertensive rats. Circulation 96: 1991-1998.
28. Oliver PM, Fox JE, Kim R, Rockman HA, Kim HS, Reddick RL et al. (1997). Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. Proc Natl Acad Sci USA 94: 14731-14735.
29. Pegram BL, Ischise S, Frolich ED (1982). Effect of methyldopa, clonidine, and hydralazine on cardiac mass and haemodynamicsin Wistar-Kyoto and SHR. Cardiovasc Res 16: 40-46.
30. Rubattu S, Bigatti G, Evangelista A, Lanzani C, Stanzione R, Zagato L et al. (2006). Association of atrial natriuretic peptide and type a natriuretic peptide receptor gene polymorphisms with left ventricular mass in human essential hypertension. J Am Coll Cardiol 48: 499-505.
31. 2+blockers prevent myocardial remodeling induced by chronic NO inhibition in rats. Hypertension 41: 963-967.
32. Sen S, Tarazi RC, Bumpus FM (1974). Cardiac hypertrophy in SHR. Circ Res 35: 775-781.
33. Sen S, Tarazi RC, Bumpus FM (1977). Cardiac hypertrophy and antihypertensive therapy. Cardiovasc Res 11: 427-433. Senbonmatsu T, Ichihara S, Price E Jr, Gaffney FA, Inagami T (2000). Evidence for angiotensin II type 2 receptor-mediated cardiac myocyte enlargement during in vivo pressure overload. J Clin Invest 106: R25-R29.
34. Suzuki J, Matsubara H, Urakami M, Inada M (1993). Rat angiotensin II (type 1A) receptor mRNA regulation and subtype expression in myocardial growth and hypertrophy. Cir Res 73: 439-447.
35. Swynghedauw B (1999). Molecular mechanisms of myocardial remodeling. Physiol Rev 79: 215-262.
36. Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R Jr, Ferdinand K et al. (2004). Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 351: 2049-2057.
37. Tsoporis J, Leenen FH (1986). Effects of hydralazine on blood pressure, pressor mechanisms and cardiac hypertrophy in twokidney, one-clip hypertensive rats. Can J Physiol Pharmacol 64: 1528-1534.
38. Tsoporis J, Leenen FH (1988). Effects of arterial vasodilators on cardiac hypertrophy and sympathetic activity in rats. Hypertension 11: 376-386.
39. Tsoporis J, Yuan BX, Leenen FH (1989). Arterial vasodilators, cardiac volume load, and cardiac hypertrophy in normotensive rats. Am J Physiol 256 (3 Pt 2): H876-H880.
40. Tsotetsi OJ, Woodiwiss AJ, Netjhardt M, Qubu D, Brooksbank R, Norton GR (2001). Attenuation of cardiac failure, dilatation, damage, and detrimental interstitial remodeling without regression of hypertrophy in hypertensive rats. Hypertension 38: 846-851.
41. Tsutamoto T, Kanamori T, Wada A, Kinoshita M (1992). Uncoupling of atrial natriuretic peptide extraction and cyclic guanosine monophosphate production in the pulmonary circulation in patients with severe heart failure. J Am Coll Cardiol 20: 541-546.
42. Tsutamoto T, Kanamori T, Morigami N, Sugimoto Y, Yamaoka O, Kinoshita M (1993). Possibility of downregulation of atrial natriuretic peptide receptor coupled to guanylate cyclase in peripheral vascular beds of patients with chronic severe heart failure. Circulation 87: 70-75.
43. Tsutsumi Y, Matsubara H, Ohkubo N, Mori Y, Nozawa Y, Murasawa S et al. (1998). Angiotensin II type 2 receptor is upregulated in human heart with interstitial fibrosis, and cardiac fibroblasts are the major cell type for its expression. Cir Res 83: 1035-1046.
44. Usami S, Kishimoto I, Saito Y, Harada M, Kuwahara K, Nakagawa Y et al. (2008). Association of CT dinucleotide repeat polymorphism in the 5′-flanking region of the guanylyl cyclase (GC)-A gene with essential hypertension in the Japanese. Hypertens Res 31: 89-96.
45. Yan X, Price RL, Nakayama M, Ito K, Schuldt AJ, Manning WJ et al. (2003). Ventricular-specific expression of angiotensin II type 2 receptors causes dilated cardiomyopathy and heart failure in transgenic mice. Am J Physiol Heart Circ Physiol 285: H2179-H2187.